AK139

Phase 2Small molecule

AK139 is one of 53 small molecule programs targeting Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Rhinosinusitis With Nasal Polyps (crswnp)Not yet recruiting

AsthmaNot yet recruiting

Seasonal Allergic RhinitisNot yet recruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)Phase 2

Not yet recruiting

AsthmaPhase 2

Not yet recruiting

Seasonal Allergic RhinitisPhase 2

Not yet recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

AK139

AAkeso

Phase 2

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Aclidinium Bromide

Atrovent

2 9

Ozone

TTanta University

Preclinical

1 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Asthma

NCT07436221

Q2 2027

Phase 2Not yet recruiting

Seasonal Allergic Rhinitis

NCT07436234

Q3 2027

Phase 2Not yet recruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)

NCT07755371

Clinical

Trials by Indication[1]

Seasonal Allergic Rhinitis1 trial

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis

Not yet recruiting·AAkeso·Phase 2·NCT07436234·111 enrolled

Asthma1 trial

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma

Not yet recruiting·AAkeso·Phase 2·NCT07436221·160 enrolled

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps

Not yet recruiting·AAkeso·Phase 2·NCT07755371·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AK139. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AK139 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AK139. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Akeso company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAkeso

AK139

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Seasonal Allergic Rhinitis1 trial

Asthma1 trial

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)1 trial

References

Drug Info

Quick Facts

Related News